A pilot study to examine the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people

Examining the effectiveness, safety and tolerability of 12 weeks of treatment with low-dose quetiapine (100-400 mg/day) in anorexia nervosa patients aged between 15 and 44 years in improving participants' physical and psychological health status

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000521224

Enrollment

Registered

2009-06-30

Start date

2004-03-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The aim of this study was to determine whether a new antipsychotic medication, quetiapine (Seroquel) is a safe and effective treatment for young people with anorexia nervosa

Interventions

oral low-dose quetiapine therapy 100-400 mg/day for a total of 12 weeks, together with treatment as usual (cognitive behavioural therapy (CBT), individual, family, and supportive psychotherapy) for 12 weeks.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

15 Years to 44 Years

Healthy volunteers

Inclusion criteria

A Diagnostic and Statistical Manual for Psychiatric Disorders IV (DSM-IV) diagnosis of anorexia nervosa No history of treatment with an atypical antipsychotic, though treatment for less than 7 days was considered acceptable

Exclusion criteria

Treatment with an atypical antipsychotic drug for longer than 7 days, comorbid psychotic illness, history of brain infarction or brain surgery, diabetes, an intelligence quotient (IQ) of less than 70

Outcome results